Related Experiment Video
Updated: Jun 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Incretin therapies: effects beyond glycemic control
Sunder Mudaliar1, Robert R Henry
1Section of Diabetes/Metabolism, VA San Diego HealthCare System, San Diego California 92161, USA. smudaliar@vapop.ucsd.edu
The American Journal of Medicine
|May 26, 2009
Summary
Incretin-based therapies offer benefits beyond blood sugar control for type 2 diabetes, potentially improving cardiovascular health and halting disease progression.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Disease in Diabetes
Background:
- Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion and progressive beta-cell dysfunction.
- Incretin hormones and incretin-based therapies are crucial for managing glycemic control and beta-cell function in T2DM.
Purpose of the Study:
- To review the
- beyond-glycemic
- benefits of incretin-based therapies in T2DM patients.
- To explore how these benefits may reduce the cardiovascular burden in individuals with diabetes.
Main Methods:
- Review of scientific literature on incretin-based pharmacotherapies.
- Analysis of data on weight reduction, blood pressure, lipid profiles, and cardiovascular function.
Main Results:
- Incretin-based therapies demonstrate benefits beyond glycemic control, including weight reduction and improved lipid profiles.
- These therapies may positively impact myocardial and endothelial function, contributing to cardiovascular health.
- Potential to alter disease progression by preserving beta-cell function.
Conclusions:
- Incretin-based therapies offer multifaceted advantages for T2DM management, extending to cardiovascular risk reduction.
- These agents may play a significant role in ameliorating the cardiovascular burden associated with diabetes.
- Further research into the long-term cardiovascular outcomes of incretin-based therapies is warranted.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...